Cardinal Health 108 dba Metro Medical

The Florida Department of Health (DOH), Division of Disease Control and Health Protection, is seeking to procure a single-source procurement for Sirturo (Bedaquline) medication from Cardinal Health 108 dba Metro Medical. The procurement is specifically designed to purchase medication used to treat multi-drug-resistant strains of tuberculosis, with the medication to be ordered in bulk using 340B pricing, prescribed by the State Tuberculosis Medical Director, and dispensed by the State Pharmacy. This procurement is being conducted in accordance with Chapter 60A-1.045 of the Florida Administrative Code, with the agency seeking authorization for a direct purchase from the sole wholesale distributor of this specialized medication. The contract opportunity is posted for Leon County and spans a three-year period, with the procurement notice published on March 27, 2025, and a response deadline of April 17, 2025. The primary objective is to control tuberculosis infections and mitigate their effects by securing a critical, specialized antitubercular medication that is uniquely positioned to address specific multi-drug-resistant tuberculosis strains.

The procurement appears to be a non-competitive, single-source acquisition with no explicit set-aside designations or restrictions on respondent organizations. The estimated contract value is $300,000.00, with Cardinal Health 108 dba Metro Medical identified as the exclusive wholesale distributor of Sirturo (Bedaquline) 100 MG tablets. The DOH has structured this procurement as an invitation for potential vendors to provide information about their ability to supply comparable commodities or services, though the documentation suggests a high likelihood of proceeding with Cardinal Health as the sole source vendor. No specific disadvantaged enterprise requirements or integration considerations are explicitly outlined in the procurement documents. The contract will leverage 340B pricing mechanisms, indicating potential cost efficiencies for the state's pharmaceutical procurement. Prospective vendors are encouraged to review the detailed specification in the EXP2613 PUR7776.pdf document and provide any relevant alternative sourcing information before the April 17, 2025 deadline.